Sara Bonstein Sells 3,470 Shares of Insmed Incorporated (NASDAQ:INSM) Stock

Insmed Incorporated (NASDAQ:INSM - Get Free Report) CFO Sara Bonstein sold 3,470 shares of the firm's stock in a transaction that occurred on Tuesday, January 7th. The stock was sold at an average price of $65.70, for a total transaction of $227,979.00. Following the completion of the transaction, the chief financial officer now directly owns 114,736 shares in the company, valued at approximately $7,538,155.20. The trade was a 2.94 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Sara Bonstein also recently made the following trade(s):

• On Friday, January 10th, Sara Bonstein sold 1,066 shares of Insmed stock. The stock was sold at an average price of $63.72, for a total transaction of $67,925.52.

Insmed Price Performance

Shares of Insmed stock traded down $0.47 during trading on Friday, reaching $65.25. 3,087,759 shares of the stock traded hands, compared to its average volume of 1,881,810. Insmed Incorporated has a 52-week low of $21.92 and a 52-week high of $80.53. The company has a debt-to-equity ratio of 2.03, a current ratio of 6.37 and a quick ratio of 5.99. The business has a fifty day simple moving average of $71.29 and a two-hundred day simple moving average of $72.44. The company has a market capitalization of $11.67 billion, a price-to-earnings ratio of -11.76 and a beta of 1.12.

Insmed (NASDAQ:INSM - Get Free Report) last released its quarterly earnings results on Thursday, October 31st. The biopharmaceutical company reported ($1.27) earnings per share for the quarter, missing the consensus estimate of ($1.19) by ($0.08). The business had revenue of $93.40 million during the quarter, compared to analyst estimates of $93.36 million. Insmed's quarterly revenue was up 18.1% compared to the same quarter last year. During the same period in the previous year, the company earned ($1.10) EPS. Sell-side analysts expect that Insmed Incorporated will post -5.44 EPS for the current year.

Institutional Investors Weigh In On Insmed

A number of hedge funds have recently bought and sold shares of the business. Geode Capital Management LLC boosted its holdings in shares of Insmed by 4.7% in the 3rd quarter. Geode Capital Management LLC now owns 3,813,384 shares of the biopharmaceutical company's stock worth $278,432,000 after purchasing an additional 172,664 shares during the period. Darwin Global Management Ltd. purchased a new position in Insmed during the second quarter worth $237,076,000. Principal Financial Group Inc. increased its position in Insmed by 12.9% during the third quarter. Principal Financial Group Inc. now owns 1,871,890 shares of the biopharmaceutical company's stock valued at $136,648,000 after acquiring an additional 214,130 shares during the last quarter. Clearbridge Investments LLC raised its stake in shares of Insmed by 76.8% in the second quarter. Clearbridge Investments LLC now owns 1,644,948 shares of the biopharmaceutical company's stock valued at $110,212,000 after acquiring an additional 714,539 shares during the period. Finally, Vestal Point Capital LP lifted its holdings in shares of Insmed by 113.3% in the 3rd quarter. Vestal Point Capital LP now owns 1,600,000 shares of the biopharmaceutical company's stock worth $116,800,000 after acquiring an additional 850,000 shares during the last quarter.

Analyst Ratings Changes

INSM has been the subject of several analyst reports. JPMorgan Chase & Co. upped their price objective on Insmed from $74.00 to $83.00 and gave the stock an "overweight" rating in a research note on Friday, November 22nd. Truist Financial reaffirmed a "buy" rating and issued a $105.00 price objective (up previously from $100.00) on shares of Insmed in a research note on Friday, November 1st. Bank of America boosted their price objective on Insmed from $84.00 to $86.00 and gave the company a "buy" rating in a research note on Wednesday, October 9th. Finally, HC Wainwright restated a "buy" rating and set a $90.00 target price on shares of Insmed in a research note on Friday, November 1st. One research analyst has rated the stock with a sell rating and sixteen have issued a buy rating to the stock. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus target price of $83.67.

About Insmed

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.